BSD Medical Reports German Radiation Oncology Society 2012 Deep Hyperthermia Treatment Guidelines Support BSD-2000 Technology

  BSD Medical Reports German Radiation Oncology Society 2012 Deep Hyperthermia
  Treatment Guidelines Support BSD-2000 Technology

Business Wire

SALT LAKE CITY -- November 08, 2012

BSD Medical Corporation (NASDAQ: BSDM) today announced that the German Society
of Radiation Oncology (DEGRO) has published quality assurance guidelines for
deep hyperthermia that support the advanced phased array technology utilized
in the BSD-2000 Hyperthermia System. The press release from DEGRO states that
the addition of hyperthermia to standard radiotherapy and/or chemotherapy
improves the outcome for patients with high risk sarcomas, breast cancer
recurrence, superficial tumors, head and neck cancer, cervical cancer,
pancreatic cancer, bladder cancer, and rectal cancer. The press release
explains that DEGRO is issuing quality assurance guidelines for deep
hyperthermia equipment that have been agreed on by a consortium of treatment
centers and that the guidelines are expected to improve the delivery of deep
hyperthermia. The BSD-2000 Hyperthermia System provides the quality assurance
and treatment delivery requirements included in the DEGRO press release for
effective delivery of deep hyperthermia.

About DEGRO

The German Society of Radiation Oncology (DEGRO – Deutsche Gesellschaft für
Radio-Onkologie) is the largest radiation oncology organization in Germany and
has more than 2,500 members. The world’s longest running scientific journal in
radiation oncology, “Strahlentherapie und Onkologie,” is the official
publication of DEGRO.

About the BSD-2000 Hyperthermia System

The BSD-2000 – developed and patented exclusively by BSD – delivers localized
therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The
BSD-2000 creates a central focusing of energy that can be electronically
focused to target the shape, size and location of the tumor, thus providing
dynamic control of the heating delivered to the tumor region. The BSD-2000 has
Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and
Drug Administration (FDA) for use in conjunction with radiation therapy for
the treatment of cervical cancer patients who are ineligible for chemotherapy.
The BSD-2000 also has CE (Conformité Européenne) Marking approval for the
commercial sale in Europe. CE Marking approval is also recognized in many
countries outside of the EU.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy, which is delivered
using focused radiofrequency (RF) and microwave energy. BSD’s product lines
include both hyperthermia and ablation treatment systems. BSD’s hyperthermia
cancer treatment systems, which have been in use for several years in the
United States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

Statements contained in this press release that are not historical facts are
forward-looking statements, as defined in the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are subject to risks and
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date on which such statements are made, and the Company undertakes no
obligation to update such statements to reflect events or circumstances
arising after such date.

Contact:

BSD Medical Corporation
Dennis Gauger, 801-972-5555
dgauger@bsdmc.com
fax: 801-972-5930